Taliglucerase alfa (Elelyso)

Elelyso (taliglucerase alfa) is covered only for the FDA‑approved indication of Type 1 Gaucher disease in patients aged ≥4 years (other indications excluded), with approvals limited to 1 year. Coverage requires documented deficient β‑glucocerebrosidase activity or molecular genetic confirmation, prescription by or consultation with a geneticist/endocrinologist/metabolic or lysosomal storage disorder specialist, documentation of age/diagnosis, and dosing limited to 60 U/kg IV no more frequently than every 2 weeks.

"Elelyso is indicated for the treatment of individuals with Type 1 Gaucher disease."

Sign up to see full coverage criteria, indications, and limitations.